TABLE 1.
Fluconazole susceptibilities of 702 isolates of Candida species as determined by the Vitek 2 AF03 IUO yeast susceptibility test and the CLSI BMD methoda
| Species (no. of isolates tested) and test method | MIC (μg/ml) |
EA (%) | ||
|---|---|---|---|---|
| Range | 50% of strains | 90% of strains | ||
| C. albicans (215) | ||||
| Vitek 2 | ≤0.5–≥64 | ≤0.5 | 1 | 95.8 |
| BMD | ≤0.25–≥256 | ≤0.25 | 1 | |
| C. glabrata (181) | ||||
| Vitek 2 | 1–≥64 | 8 | ≥64 | 88.4 |
| BMD | 0.5–≥256 | 4 | 64 | |
| C. parapsilosis (109) | ||||
| Vitek 2 | 0.5–≥64 | ≤0.5 | 8 | 99.1 |
| BMD | ≤0.25–64 | 0.5 | 8 | |
| C. tropicalis (107) | ||||
| Vitek 2 | ≤0.5–≥64 | 1 | 8 | 94.4 |
| BMD | ≤0.25–≥256 | ≤0.25 | 4 | |
| C. krusei (30) | ||||
| Vitek 2 | 4–≥64 | 16 | 32 | 93.3 |
| BMD | 2–≥256 | 16 | 32 | |
| C. lusitaniae (28) | ||||
| Vitek 2 | ≤0.5–≥64 | ≤0.5 | 2 | 92.9 |
| BMD | ≤0.25–128 | ≤0.25 | 1 | |
| C. dubliniensis (13) | ||||
| Vitek 2 | ≤0.5–1 | ≤0.5 | 1 | 100 |
| BMD | ≤0.25 | ≤0.25 | ≤0.25 | |
| C. guilliermondii (8) | ||||
| Vitek 2 | ≤0.5–2 | 2 | 100 | |
| BMD | ≤0.25–4 | 2 | ||
| C. pelliculosa (4) | ||||
| Vitek 2 | 2 | 2 | 100 | |
| BMD | 1–2 | 2 | ||
| C. kefyr (3) | ||||
| Vitek 2 | 1–2 | 1 | 66.7 | |
| BMD | ≤0.25–0.5 | ≤0.25 | ||
| C. utilis (2) | ||||
| Vitek 2 | 2–8 | 2 | 100 | |
| BMD | 2–4 | 2 | ||
| C. haemulonii (1) | ||||
| Vitek 2 | ≤0.5 | 100 | ||
| BMD | ≤0.25 | |||
| C. norvegensis (1) | ||||
| Vitek 2 | 8 | 100 | ||
| BMD | 8 | |||
| All Candida species (702) | ||||
| Vitek 2 | ≤0.5–≥64 | 1 | 32 | 94.0 |
| BMD | ≤0.25–≥256 | 0.5 | 16 | |
a
Isolates included both clinical (n = 584) and challenge (n = 118) sets. BMD results were read at 24 h of incubation. Percent, EA (±2 log2 dilutions) between Vitek 2 and CLSI BMD MICs is shown.